Drugs / FLUAD Quadrivalent
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT07485855 | Dec 2025 → Apr 2027 expected | hematopoietic and lymphoid cell neoplasm, influenza | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06054269 | Nov 2022 → Jul 2023 | influenza | Centers for Disease Control and Prevention | Completed | Mixed |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05007041 Comparator | Sep 2021 → Mar 2023 | — | Duke University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluad Quadrivalent | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗ |
| Known as | aIIV4 | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗ |
| Modality | Vaccine | “Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®)” NCT05007041 ↗ |
| Route | Intramuscular | “intramuscular dose of FLUAD Quadrivalent” NCT06054269 ↗ |